NDA 019667 · Novartis
Sandostatin
Octreotide Acetate · Injection
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Oct 21, 1988
Approved uses
2
Original approval plus efficacy supplements
Registered trials
283
74 Phase 3, 26 recruiting
FAERS reports
9,636
7,955 serious, 1,880 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 22, 2026.
Sandostatin Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection; these trials were not optimally designed to detect such effects. ( 1.4 ) 1.1 Acromegaly Sandostatin Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. 1.2 Carcinoid Tumors Sandostatin Injection is indicated for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. 1.3 Vasoactive Intestinal Peptide Tumors Sandostatin Injection is indicated for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas)-secreting tumors. 1.4 Important Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in...
Mechanism: Sandostatin Injection exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, VIP, secretin, motilin, and pancreatic polypeptide. By virtue of these pharmacological actions, octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and VIP...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 3, 1994 Supplement 17 · Efficacy
- Oct 21, 1988 Original approval · Type 1 - New Molecular Entity · priority review
5 products under this application
- SANDOSTATIN · OCTREOTIDE ACETATE EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- SANDOSTATIN · OCTREOTIDE ACETATE EQ 0.5MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
- SANDOSTATIN · OCTREOTIDE ACETATE EQ 0.05MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
- SANDOSTATIN · OCTREOTIDE ACETATE EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
- SANDOSTATIN · OCTREOTIDE ACETATE EQ 0.1MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Octreotide" as an intervention, any sponsor and status, largest first.
University Hospital, Basel, SwitzerlandAcademic, hospital or other
NCT00978211 · 1,499 participants · Start Sep 1997 · Primary completion Sep 2013
Drug: DOTA-TOC Treatment · For: Neuroendocrine Tumors
Sites: Basel, Switzerland
- Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal BleedingPivotal-lookingCompleted
Korea UniversityAcademic, hospital or other
NCT00966355 · 1,034 participants · Start Sep 2006 · Primary completion May 2010
Drug: Terlipressin; Somatostatin and 1 more · For: Variceal Bleeding, Cirrhosis
Sites: Seoul, South Korea
- Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT00002864 · 667 participants · Start Sep 24, 1996 · Primary completion Dec 7, 2007
Drug: octreotide acetate; tamoxifen citrate · For: Breast Cancer
Sites: Duluth, Minnesota; Surrey, Canada; Vancouver, Canada · 40 sites in all
- Prevention of Postoperative Pancreatic Fistula by SomatostatinPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT03000946 · 655 participants · Start May 15, 2017 · Primary completion Feb 9, 2021
Drug: Somatostatin; Octreotide · For: Pancreatic Surgery
Sites: Paris, France · 2 sites in all
- Octreotide Acetate in Microspheres in Patients With Diabetic RetinopathyPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00131144 · 583 participants · Start Nov 1999 · Primary completion Dec 2005
Drug: Octreotide Acetate in Microspheres 20 mg; Octreotide Acetate in Microspheres and 1 more · For: Diabetic Retinopathy
Sites: East Hanover, New Jersey
- Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal CancerPivotal-lookingCompleted
Eastern Cooperative Oncology GroupResearch network
NCT00003057 · 500 participants (planned) · Start Mar 26, 1997 · Primary completion May 2000
Drug: loperamide hydrochloride; octreotide acetate · For: Colorectal Cancer; Diarrhea
Sites: La Jolla, California; San Francisco, California; Wilmington, Delaware · 33 sites in all
- Everolimus and Octreotide in Patients With Advanced Carcinoid TumorPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00412061 · 429 participants · Start Dec 2006 · Primary completion Apr 2010
Drug: Octreotide; Placebo and 1 more · For: Carcinoid Tumor; Malignant Carcinoid Syndrome
Sites: Tucson, Arizona; Fayetteville, Arkansas; Little Rock, Arkansas · 70 sites in all
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00569127 · 427 participants · Start Dec 1, 2007 · Primary completion Jan 1, 2015
Drug: Bevacizumab; Octreotide Acetate and 1 more · For: Colorectal Neuroendocrine Tumor G1; Gastric Neuroendocrine Tumor G1; Neuroendocrine Neoplasm and 2 more
Sites: Mobile, Alabama; Fairbanks, Alaska; Fort Smith, Arkansas · 493 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea2,155
- fatigue1,847
- blood pressure increased1,658
- nausea1,529
- blood pressure systolic increased1,409
- malaise1,232
- abdominal pain1,227
- death1,219
- pain1,197
- injection site pain1,138
- asthenia1,064
- weight decreased1,043
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 111 |
| 2005 | 101 |
| 2006 | 119 |
| 2007 | 102 |
| 2008 | 144 |
| 2009 | 187 |
| 2010 | 291 |
| 2011 | 319 |
| 2012 | 346 |
| 2013 | 255 |
| 2014 | 372 |
| 2015 | 559 |
| 2016 | 531 |
| 2017 | 649 |
| 2018 | 795 |
| 2019 | 1,050 |
| 2020 | 1,100 |
| 2021 | 602 |
| 2022 | 561 |
| 2023 | 526 |
| 2024 | 402 |
| 2025 | 271 |
| 2026 | 243 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sandostatin (Octreotide Acetate)
2024 spending
$197K
Beneficiaries
35
102 claims
Per beneficiary
$5,627
$25.52 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $249,704 |
| 2021 | $247,190 |
| 2022 | $199,576 |
| 2023 | $169,357 |
| 2024 | $196,939 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus highߛdose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Singh S, Halperin D, Myrehaug S, et al. · Lancet 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial.
Goltstein LCMJ, Grooteman KV, Bernts LHP, et al. · Gastroenterology 2024 · Multicenter Study, Randomized Controlled Trial
- 177Lu-Dotatate plus long-acting octreotide versus highߛdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, et al. · Lancet Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A, Müller HH, Schade-Brittinger C, et al. · J Clin Oncol 2009 · Clinical Trial, Phase III, Multicenter Study
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
Rinke A, Wittenberg M, Schade-Brittinger C, et al. · Neuroendocrinology 2017 · Randomized Controlled Trial
- One vs Five Days of Octreotide Infusion for Acute Esophageal Variceal Bleeding: A Randomized Controlled Trial.
Chirapongsathorn S, Chang A, Malikhao S, et al. · Am J Gastroenterol 2026 · Multicenter Study, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.